000179389 001__ 179389
000179389 005__ 20240229145542.0
000179389 0247_ $$2doi$$a10.1038/s41416-022-01792-9
000179389 0247_ $$2pmid$$apmid:35354948
000179389 0247_ $$2ISSN$$a0007-0920
000179389 0247_ $$2ISSN$$a1532-1827
000179389 0247_ $$2altmetric$$aaltmetric:125602614
000179389 037__ $$aDKFZ-2022-00640
000179389 041__ $$aEnglish
000179389 082__ $$a610
000179389 1001_ $$aRobinson, Natassia$$b0
000179389 245__ $$aAnti-cancer therapy is associated with long-term epigenomic changes in childhood cancer survivors.
000179389 260__ $$aEdinburgh$$bNature Publ. Group$$c2022
000179389 3367_ $$2DRIVER$$aarticle
000179389 3367_ $$2DataCite$$aOutput Types/Journal article
000179389 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1662032094_21383
000179389 3367_ $$2BibTeX$$aARTICLE
000179389 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000179389 3367_ $$00$$2EndNote$$aJournal Article
000179389 500__ $$a2022 Jul;127(2):288-300
000179389 520__ $$aChildhood cancer survivors (CCS) exhibit significantly increased chronic diseases and premature death. Abnormalities in DNA methylation are associated with development of chronic diseases and reduced life expectancy. We investigated the hypothesis that anti-cancer treatments are associated with long-term DNA methylation changes that could be key drivers of adverse late health effects.Genome-wide DNA methylation was assessed using MethylationEPIC arrays in paired samples (before/after therapy) from 32 childhood cancer patients. Separately, methylation was determined in 32 samples from different adult CCS (mean 22-years post-diagnosis) and compared with cancer-free controls (n = 284).Widespread DNA methylation changes were identified post-treatment in childhood cancer patients, including 146 differentially methylated regions (DMRs), which were consistently altered in the 32 post-treatment samples. Analysis of adult CCS identified matching methylation changes at 107/146 of the DMRs, suggesting potential long-term retention of post-therapy changes. Adult survivors also exhibited epigenetic age acceleration, independent of DMR methylation. Furthermore, altered methylation at the DUSP6 DMR was significantly associated with early mortality, suggesting altered methylation may be prognostic for some late adverse health effects in CCS.These novel methylation changes could serve as biomarkers for assessing normal cell toxicity in ongoing treatments and predicting long-term health outcomes in CCS.
000179389 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000179389 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000179389 7001_ $$aCasement, John$$b1
000179389 7001_ $$aGunter, Marc J$$b2
000179389 7001_ $$00000-0003-3838-855X$$aHuybrechts, Inge$$b3
000179389 7001_ $$aAgudo, Antonio$$b4
000179389 7001_ $$00000-0002-9972-9779$$aBarranco, Miguel Rodríguez$$b5
000179389 7001_ $$aEichelmann, Fabian$$b6
000179389 7001_ $$0P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aJohnson, Theron$$b7$$udkfz
000179389 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b8$$udkfz
000179389 7001_ $$00000-0001-5438-970X$$aPala, Valeria$$b9
000179389 7001_ $$aPanico, Salvatore$$b10
000179389 7001_ $$aSandanger, Torkjel M$$b11
000179389 7001_ $$aSchultze, Matthias B$$b12
000179389 7001_ $$aTravis, Ruth C$$b13
000179389 7001_ $$00000-0003-2666-414X$$aTumino, Rosario$$b14
000179389 7001_ $$aVineis, Paolo$$b15
000179389 7001_ $$00000-0003-2237-0128$$aWeiderpass, Elisabete$$b16
000179389 7001_ $$aSkinner, Roderick$$b17
000179389 7001_ $$00000-0001-9515-1722$$aSharp, Linda$$b18
000179389 7001_ $$aMcKay, Jill A$$b19
000179389 7001_ $$00000-0001-9681-8429$$aStrathdee, Gordon$$b20
000179389 773__ $$0PERI:(DE-600)2002452-6$$a10.1038/s41416-022-01792-9$$n2$$p288-300$$tBritish journal of cancer$$v127$$x0007-0920$$y2022
000179389 909CO $$ooai:inrepo02.dkfz.de:179389$$pVDB
000179389 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000179389 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000179389 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000179389 9141_ $$y2022
000179389 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000179389 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-28
000179389 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000179389 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRIT J CANCER : 2021$$d2022-11-15
000179389 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-15
000179389 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-15
000179389 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-15
000179389 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-15
000179389 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-15
000179389 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-15
000179389 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-15
000179389 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-15
000179389 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-15
000179389 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBRIT J CANCER : 2021$$d2022-11-15
000179389 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000179389 980__ $$ajournal
000179389 980__ $$aVDB
000179389 980__ $$aI:(DE-He78)C020-20160331
000179389 980__ $$aUNRESTRICTED